Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.49 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 4/20 | 0.39 |
| ▸ | PRKCI | P41743 | 2/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | CCNK | O75909 | 1/20 | 0.39 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.39 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | CIT | O14578 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1328384 | 0.85 | NUDT1 (0.44) | BRD4AAK1AXLCIT | |
| SCHEMBL858643 | 0.84 | TTBK1 (0.46) | BRD4ROCK2ROCK1PRKCIAXL | |
| SCHEMBL1328773 | 0.83 | BRD4 (0.48) | BRD4AAK1ROCK1PRKCIAXL | |
| SCHEMBL1329521 | 0.83 | CCNK (0.44) | BRD4AAK1ROCK2ROCK1PRKCI | |
| SCHEMBL1327890 | 0.82 | BRD4 (0.47) | BRD4AAK1ROCK2KIT | |
| SCHEMBL1329848 | 0.82 | AAK1 (0.52) | BRD4AAK1ROCK2ROCK1CCNK | |
| SCHEMBL1327827 | 0.81 | BRD4 (0.48) | BRD4AAK1ROCK1PRKCIAXL | |
| SCHEMBL1329294 | 0.81 | GRM5 (0.46) | BRD4AAK1PRKCIAXLCCNK | |
| SCHEMBL1328009 | 0.79 | PRKCI (0.44) | BRD4AAK1ROCK1PRKCIAXL | |
| SCHEMBL1328118 | 0.79 | GRM5 (0.51) | BRD4AAK1PRKCIAXLCCNK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110282056-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-11-17 | — | — | US | claimed |
| US-20110282056-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110282056-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MAP3K19, MAP3K20, MAP3K1 | BRD4 1599/4885AAK1 218/4885ROCK2 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.